Here's what you need to know about the four CFTR (cystic fibrosis transmembrane conductance regulator) modulators.
Site Search
Historic Time in Treatment of Rare Disease as Promising Drugs Reach Phase 3 Trials
Legislation to Help Speed Research for Cystic Fibrosis and Other Rare Diseases
Bill Would Remove Financial Penalties for Participating in Research Studies
Kalydeco Marks the Latest Success of the Cystic Fibrosis Foundation’s Venture Philanthropy Model
CF Foundation Provided Scientific, Clinical and Significant Funding Support in Drug Development Process
CFF-Championed Bill Eliminates Barriers to Participation in Clinical Trials for People with CF and other Rare Diseases
Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.